Mark Louis Brantly MD
Asthma & COPD, Cystic Fibrosis
UF Chief, Pulmonary, Critical Care and Sleep Medicine
Join to View Full Profile
1600 SW Archer RdGainesville, FL 32610
Phone+1 352-273-8737
Fax+1 352-627-4268
Dr. Brantly is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Old Dominion UniversityResidency, Internal Medicine, 1980 - 1983- Eastern Virginia Medical SchoolInternship, Transitional Year, 1979 - 1980
University of Florida College of MedicineClass of 1979
Certifications & Licensure
FL State Medical License 1998 - 2025
NC State Medical License 1982 - 2024
VA State Medical License 1981 - 2018
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
Clinical Trials
- 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? Start of enrollment: 2001 Nov 01
- Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency Start of enrollment: 2004 Mar 01
- Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency Start of enrollment: 2003 Jan 07
Publications & Presentations
PubMed
- 3 citationsMulti-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver...Rohit Loomba, Virginia C Clark, Mattias Mandorfer, Marc Miravitlles, Mark Brantly
Gastroenterology. 2026-04-01 - Adaptive Regulation of mTOR Activity by AMPK, Akt, and ATF6 Pathways in Pi*Z Alpha-1 Antitrypsin Deficient Hepatocytes.Yuanqing Lu, Jungnam Lee, Naweed Mohammad, Mark L Brantly
Biomolecules. 2026-03-27 - Alpha-defensins promote macrophage inflammatory activation via RNF31 signaling.Jungnam Lee, Naweed Mohammad, Seyoung Mun, Kyudong Han, Tammy Flagg-Dowie
Genes & Genomics. 2026-03-01
Press Mentions
Pioneering Discussions at IISLD 2024: Advancing Treatment for PBC and Alpha-1 Antitrypsin DeficiencyOctober 11th, 2024- Chronic Obstructive Pulmonary Diseases: Journal of the COPD FoundationOctober 1st, 2024
- UF Health Enrolls Its First Patients to Begin Clinical Trials to Treat COVID-19November 9th, 2020
Grant Support
- The Miles TrialNational Center For Research Resources2009
- QuantumNational Center For Research Resources2009
- Pirfenidone And Patients With Idiopathic Pulmonary Fibrosis (IPF)National Center For Research Resources2009
- Clinical Trial: Tobacco Smoke Induced Cell Injury In Lung CompartmentsNational Center For Research Resources2008–2009
- Clinical Trial: Phase I Trial Of Intramuscular Injection Of Raav1-Cb-HaatNational Center For Research Resources2008–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
